We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Novel Cardiovascular Biomarker Secretoneurin Implicated in Arrhythmogenesis

By LabMedica International staff writers
Posted on 21 Oct 2021
Print article
Image: Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) is caused by a build-up of fatty deposits and fibrous tissue on the right ventricle, the chamber of the heart that pumps blood into the lungs (Photo courtesy of National Heart Foundation of Australia)
Image: Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) is caused by a build-up of fatty deposits and fibrous tissue on the right ventricle, the chamber of the heart that pumps blood into the lungs (Photo courtesy of National Heart Foundation of Australia)
Secretoneurin is a 33-amino acid peptide derived from neuroendocrine and myocardial tissue that belongs to the granin protein family. Secretoneurin may play a role in regulating processes in the myocardium, including cardiomyocyte Ca2+ handling, and has been implicated in arrhythmogenesis.

Those affected by arrhythmogenic cardiomyopathy may not have any symptoms at all despite having significant abnormalities in the structure of their hearts. If symptoms do occur, the initial presentation is often due to abnormal heart rhythms (arrhythmias) which in arrhythmogenic cardiomyopathy may take the form of palpitations, or blackouts.

An international team of medical scientists led by those at the Haukeland University Hospital (Bergen, Norway) included 30 healthy volunteers in a study that examined the within subject variation (CVI), between subject variation (CVG), reference change values (RCV) and index of individuality (II) of secretoneurin. Inclusion criteria were subjects 18-75 years old who reported being generally healthy, with no history of diabetes, cardiovascular disease, renal disease, chronic lung disease or cancer. The median age of the participants was 36 years and 53% were female. Secretoneurin was measured in duplicate using an ELISA (CardiNor AS, Oslo, Norway).

The investigators reported that non-fasting glucose, eGFR (CKD-EPI), cardiac troponin T (cTnT), and brain natriuretic peptide (NT-proBNP) concentrations were within the normal range for the volunteers. Median secretoneurin concentrations for females were 35 pmol/L and for males 33 pmol/L, (P-value < 0.001). CVI and CVG were 9.8% (CI 8.7% - 11.0%) and 20.0 (CI 15.4% - 28.0%), respectively. RCV were 38.7% (CI 35.5% to 42.7%) and -27.9 (CI -29.9 to -26.2) and the II were 0.60 (CI 0.42 -0.78). No gender differences were found.

The authors concluded that this study is the first to report biological variation, RCV, II and analytical quality specifications for secretoneurin. Overall low values were found indicating that secretoneurin has characteristics suitable for a biomarker that could be useful for diagnosing and monitoring disease. The study was published on October 6, 2021 in the journal Clinical Biochemistry.

Related Links:
Haukeland University Hospital
CardiNor AS


Gold Supplier
Lactate Dehydrogenase (LDH) Assay
LDH 21 FS
New
Nucleic Acid Purification System
CloNext 24
New
Cytology Sample Processor
SDSCP9000 CytoPath Processor
New
Silver Supplier
COVID-19 Ag Self Test
OnSite COVID-19 Ag Self Test

Print article

Channels

Molecular Diagnostics

view channel
Image: The TruSight RNA Fusion Panel kit provides comprehensive gene fusion detection in formalin-fixed, paraffin-embedded (FFPE) and other cancer samples (Photo courtesy of Illumina)

Targeted RNA-Sequencing Panel Detects Gene Fusions in Solid Tumors

Increasingly, rearrangements resulting in gene fusions have been revealed in multiple tumor types across diverse organ systems. These gene fusions can drive tumorigenesis by altering gene expression and activity.... Read more

Hematology

view channel
Image: Blood smear from a patient with low grade follicular lymphoma in leukemic phase: note cleaved nuclei (coffee bean cells) and scant cytoplasm (Photo courtesy of Kyle Bradley, MD)

Classification of Mature B-Cell Neoplasms Employing Standardized Flow Cytometry

The classification of lymphoid neoplasms integrates clinical, pathological, immunophenotypic, genetic, and molecular data in order to distinguish between mature B-cell lymphoma entities.... Read more

Immunology

view channel
Image: Procartaplex Immunoassays Kits are based on the principles of a sandwich ELISA, using two highly specific antibodies binding to different epitopes of one protein to quantitate all protein targets simultaneously (Photo courtesy of Thermo Fisher Scientific)

Assay Developed for Patient-Specific Monitoring and Treatment for Ovarian Cancer

Tumors can influence peripheral immune macroenvironment, thereby creating opportunities for non-invasive serum/plasma immunobiomarkers for immunostratification and immunotherapy designing.... Read more

Pathology

view channel
Illustration

Roche Introduces AI-Based Digital Pathology RUO Algorithms for Evaluation of Breast Cancer Markers

Roche (Basel, Switzerland) has announced the research use only (RUO) launch of three new automated digital pathology algorithms, uPath Ki-67 (30-9), uPath ER (SP1) and uPath PR (1E2) image analysis for... Read more

Technology

view channel
Image: PKeye Workflow Monitor System (Photo courtesy of PerkinElmer, Inc.)

PerkinElmer’s New Cloud-Based Platform Enables Laboratory Personnel to Remotely Manage Its Instruments in Real-Time

PerkinElmer, Inc. (Waltham, MA; USA) has launched its PKeye Workflow Monitor, a cloud-based platform enabling laboratory personnel to remotely manage and monitor their PerkinElmer instruments and workflows... Read more

Industry

view channel
Illustration

Global Point-of-Care Coagulation Testing Market to Be Driven by Growing Geriatric Population

The global point-of-care (POC) coagulation testing market is set to achieve significant growth on the back of the growing geriatric population and increasing technological innovations in POC testing, although... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.